Skip to main content
Anhui Wanbang Pharmaceutical Technology Co.,Ltd. logo

Anhui Wanbang Pharmaceutical Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 301520 ISIN · CNE1000068J8 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 304 across all filing types
Latest filing 2026-05-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301520

About Anhui Wanbang Pharmaceutical Technology Co.,Ltd.

https://www.ahwbyy.cn

Anhui Wanbang Pharmaceutical Technology Co., Ltd. is a comprehensive pharmaceutical research and development service provider specializing in clinical research and technical services. Operating primarily as a Contract Research Organization (CRO), the company offers a wide range of services including bioequivalence (BE) studies, Phase I through IV clinical trials, and pharmacokinetics (PK/PD) research. It provides end-to-end solutions for pharmaceutical development, encompassing clinical trial design, site management, data management, and statistical analysis. The firm focuses on supporting generic drug consistency evaluations and the development of innovative drugs. By maintaining advanced laboratory facilities and clinical research centers, the company ensures compliance with international quality standards and regulatory requirements to facilitate the market entry of diverse therapeutic products.

Recent filings

Filing Released Lang Actions
关于公司高级管理人员离任的公告
Board/Management Information Classification · 95% confidence The document is an official announcement by Anhui Wanbang Pharmaceutical Technology Co., Ltd. regarding the resignation of a senior management officer (the vice general manager). It details the departure of a senior executive, compliance with legal rules, share holdings, and confirms the management change. This clearly falls under the category of Board/Management Information (management change announcement).
2026-05-29 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the 2025 annual shareholders’ meeting resolutions for Anhui Wanbang Pharmaceutical Technology Co., Ltd., detailing meeting attendance and the voting results on multiple proposals (board report, annual report, financial statements, profit distribution, compensation plan, governance amendments, etc.). It reports the vote tallies and confirmation by legal counsel, fitting the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-15 Chinese
安徽承义律师事务所关于安徽万邦医药科技股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (法律意见书) provided by a law firm regarding the legality of the company’s 2025 annual shareholders’ meeting, including descriptions of the convening procedures, attendee qualifications, voting process, and results. It does not itself constitute the annual report, proxy solicitation materials, or financial statements, nor is it an earnings release or similar. It is an attestation/certification by external counsel, which per the Certification Rule falls under Regulatory Filings (RNS) as a fallback for officer certifications and legal opinion letters.
2026-05-15 Chinese
关于安徽万邦医药科技股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2025年度持续督导跟踪报告" which translates to "2025 Annual Continuous Supervision Follow-up Report" by the sponsor Guolian Minsheng Securities Co., Ltd. for Anhui Wanbang Pharmaceutical Technology Co., Ltd. It details the sponsor's supervision activities, including review of company disclosures, governance, fundraising supervision, onsite inspections, and other compliance and governance matters. The document is a detailed report on the sponsor's ongoing monitoring and supervision work rather than a financial report or earnings release. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. It is a specialized regulatory supervision report related to the sponsor's duties. This type of document fits best under the category of Regulatory Filings (RNS) as it is a compliance and supervisory report that does not fit other specific categories like Annual Report, Interim Report, or Audit Report. The document length is under 5,000 characters, but it is a substantive report, not just an announcement of a report publication. Therefore, the best classification is Regulatory Filings (RNS).
2026-05-07 Chinese
关于安徽万邦医药科技股份有限公司2025年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2025年度持续督导现场检查报告" which translates to "2025 Annual Continuous Supervision On-site Inspection Report" by a securities underwriting and sponsorship company regarding a listed pharmaceutical company. The content includes detailed governance, internal control, information disclosure, fundraising usage, performance, and compliance checks. It is a formal inspection report related to regulatory supervision rather than a financial report like an annual or interim report. It does not contain financial statements or earnings data but focuses on compliance, governance, and internal control inspection results. This fits the definition of an Audit Report / Information (AR), which includes standalone audit or inspection reports and regulatory stress tests, excluding full annual or interim reports. The document length is 4618 characters, sufficient for a detailed report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2025
2026-05-07 Chinese
关于举办2025年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 annual performance explanation meeting (业绩说明会) to be held on May 13, 2026. It references that the 2025 Annual Report has already been disclosed on April 23, 2026, and this meeting is intended to provide investors with further explanation and interaction regarding the company's performance and strategy. The document does not contain the actual annual report or financial data but rather invites investors to attend the meeting and submit questions. The document length is short (1070 characters) and serves as a notice for an upcoming event related to the annual report, not the report itself. Therefore, it fits the category of an Investor Presentation (IP) or possibly a Report Publication Announcement (RPA). However, since it is specifically about an "业绩说明会" (performance explanation meeting), which is a form of investor presentation focused on financial results and strategy, the best classification is Investor Presentation (IP).
2026-05-07 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.